Lipella Pharmaceuticals I... (LIPO)
Lipella Pharmaceuticals Statistics
Share Statistics
Lipella Pharmaceuticals has 2.55M shares outstanding. The number of shares has increased by -80.66% in one year.
| Shares Outstanding | 2.55M |
| Shares Change (YoY) | -80.66% |
| Shares Change (QoQ) | -84.9% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.9M |
| Failed to Deliver (FTD) Shares | 1.23K |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 2.27K, so 0.19% of the outstanding shares have been sold short.
| Short Interest | 2.27K |
| Short % of Shares Out | 0.19% |
| Short % of Float | 0.25% |
| Short Ratio (days to cover) | 0.01 |
Valuation Ratios
The PE ratio is -1.32 and the forward PE ratio is -0.84. Lipella Pharmaceuticals's PEG ratio is 0.
| PE Ratio | -1.32 |
| Forward PE | -0.84 |
| PS Ratio | 13.61 |
| Forward PS | 0.1 |
| PB Ratio | 1.95 |
| P/FCF Ratio | -1.93 |
| PEG Ratio | 0 |
Enterprise Valuation
Lipella Pharmaceuticals Inc. has an Enterprise Value (EV) of 2.97M.
| EV / Earnings | -0.64 |
| EV / Sales | 6.6 |
| EV / EBITDA | -0.64 |
| EV / EBIT | -0.62 |
| EV / FCF | -0.94 |
Financial Position
The company has a current ratio of 8.9, with a Debt / Equity ratio of 0.04.
| Current Ratio | 8.9 |
| Quick Ratio | 8.9 |
| Debt / Equity | 0.04 |
| Total Debt / Capitalization | 4.16 |
| Cash Flow / Debt | -23.06 |
| Interest Coverage | -437.5 |
Financial Efficiency
Return on equity (ROE) is -1.47% and return on capital (ROIC) is -144.65%.
| Return on Equity (ROE) | -1.47% |
| Return on Assets (ROA) | -1.29% |
| Return on Capital (ROIC) | -144.65% |
| Revenue Per Employee | $89,923.4 |
| Profits Per Employee | $-923,793 |
| Employee Count | 5 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -52.55% in the last 52 weeks. The beta is 0.15, so Lipella Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.15 |
| 52-Week Price Change | -52.55% |
| 50-Day Moving Average | 2.88 |
| 200-Day Moving Average | 3.38 |
| Relative Strength Index (RSI) | 52.38 |
| Average Volume (20 Days) | 2.29M |
Income Statement
In the last 12 months, Lipella Pharmaceuticals had revenue of 449.62K and earned -4.62M in profits. Earnings per share was -6.16.
| Revenue | 449.62K |
| Gross Profit | -2.59M |
| Operating Income | -4.75M |
| Net Income | -4.62M |
| EBITDA | -4.61M |
| EBIT | -4.75M |
| Earnings Per Share (EPS) | -6.16 |
Balance Sheet
The company has 3.29M in cash and 136.59K in debt, giving a net cash position of 3.16M.
| Cash & Cash Equivalents | 3.29M |
| Total Debt | 136.59K |
| Net Cash | 3.16M |
| Retained Earnings | -10.32M |
| Total Assets | 2.16M |
| Working Capital | 1.38M |
Cash Flow
In the last 12 months, operating cash flow was -3.15M and capital expenditures -14.43K, giving a free cash flow of -3.16M.
| Operating Cash Flow | -3.15M |
| Capital Expenditures | -14.43K |
| Free Cash Flow | -3.16M |
| FCF Per Share | -4.22 |
Margins
Gross margin is -575.87%, with operating and profit margins of -1.06K% and -1.03K%.
| Gross Margin | -575.87% |
| Operating Margin | -1.06K% |
| Pretax Margin | -1.03K% |
| Profit Margin | -1.03K% |
| EBITDA Margin | -1.02K% |
| EBIT Margin | -1.06K% |
| FCF Margin | -703.84% |
Dividends & Yields
LIPO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -236.92% |
| FCF Yield | -47.75% |
Analyst Forecast
The average price target for LIPO is $16, which is 515.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $16 |
| Price Target Difference | 515.4% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Nov 8, 2024. It was a backward split with a ratio of 1:8.
| Last Split Date | Nov 8, 2024 |
| Split Type | backward |
| Split Ratio | 1:8 |
Scores
| Altman Z-Score | 54.13 |
| Piotroski F-Score | 2 |